Intarcia Therapeutics, Inc.

Alza Corporation

Durect Corporation

Stephen A Berry

Pamela J Fereira

Houdin Dehnad

Anna Muchnik

Catherine Manya Rohloff

Aruna Nathan

Ling-Ling Kang

James B Eckenhoff

Michael A DesJardin

Rupal A Ayer

Scott D Jordan

Ekaterina S Zlatkova-Karaslavova

Gregory R Stewart

This invention relates to stable non-aqueous single phase viscous vehicles and to formulations utilizing such vehicles. The formulations comprise at least one beneficial agent uniformly suspended in the vehicle. The formulation is capable of being stored at temperatures ranging from cold to body temperature for long periods of time. The formulations are capable of being uniformly delivered from drug delivery systems at an exit shear rate of between about 1 to 1&#xd7;10reciprocal second.

Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles

The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.

Non-aqueous single phase vehicles and formulations utilizing such vehicles

Stable non-aqueous single phase viscous vehicles and formulations utlizing such vehicles

Liquid polyoxaester polymer materials are provided as suspending vehicles suitable for dispensing of pharmaceutically active agents, such as proteins, from delivery devices, for example, pump-driven dosage forms. Polyoxaesters are made from at least one diacid and at least one diol. Through the use of polyoxaesters virtually solvent-free pharmaceutical suspensions can be created.

Polyoxaester suspending vehicles for use with implantable delivery systems

Stable non- aqueous single phase viscous vehicles and formulations utilizing such vehicles

Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle

The present invention is directed to an osmotic engine useful in an osmotic delivery system for delivery of a beneficial agent in a controlled manner over a preselected administration period. By including a flowable engine comprising at least one osmotic agent and at least one fluid vehicle, the resulting osmotic engine reaches a zero order push power or push rate quickly and provides steady delivery of the beneficial agent.

Osmotic delivery system with early zero order push power engine

Performance of delivery systems for delivering beneficial agents to an animal are monitored to determine the delivery rate of the beneficial agent and the proper operation of the beneficial agent delivery device. Performance monitoring can be achieved by monitoring the physical configuration of the implanted osmotic delivery device from the exterior of the body to determine the amount of beneficial agent delivered and/or the delivery rate of the beneficial agent. The monitoring of the physical configuration of the implanted osmotic delivery device may be performed in different manners such as by X-ray or fluoroscopic monitoring of the implant structure or magnetic determination of a piston location within the implant. Performance monitoring can also be achieved by use of a performance marker within the beneficial agent to produce a specifically detectable response which can be measured noninvasively in body fluids or by-products.

Osmotic drug delivery monitoring system and method

Growing community of inventors

Hollister, CA, United States of America

Stephen A Berry